GLP-1 Weight Loss Surge Projected to Drive $13 Billion Apparel Spending Boost

The rise of GLP-1 weight loss drugs is evolving from a healthcare phenomenon into a catalyst for the U.S. retail sector. As millions of consumers experience significant weight loss, a growing number are turning to apparel retailers to replace outgrown wardrobes, creating a new revenue stream for fashion brands. This shift is being accelerated by the introduction of oral versions of these medications, which lower barriers to entry. Eli Lilly recently began shipping its pill form, Foundayo, via its direct-to-consumer platform, while Novo Nordisk's Wegovy pill saw over 600,000 prescriptions written by February. According to equity research firm Bernstein, the trend could result in a 1% to 4% increase in total U.S. clothing unit volume. This translates to between 150 million and 700 million additional items purchased annually, potentially generating up to $13 billion in extra revenue based on an average item price of $18. Market research from Circana indicates that 80% of GLP-1 users expect to need new clothing, with 55% already having made purchases. JPMorgan projects that the number of Americans on these treatments will triple from 10 million in 2026 to over 30 million by 2030. Analysts suggest the financial impact could be even higher than current estimates. Because GLP-1 users often skew toward higher income brackets, there is a strong possibility that these consumers will opt for more expensive premium brands, further increasing the average transaction value for retailers.